Back to Journals » Drug Design, Development and Therapy » Volume 3

Review

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

       
Total article views   HTML views PDF downloads Totals
8,906 Dovepress* 8,906+ 3,063 11,969
Totals 8,906 3,063 11,969
*Since 27 March 2009
+Since July 2016

View citations on Google Scholar